RxDoctor Payments Data

Mohamed Abdalla, MD

Nephrology · Flint, MINPI 1760797344

Payments from drug & device makers

$2,020in general payments, 2019–2025

Across 81 payments — averaging $24.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mallinckrodt Hospital Products Inc.$406
  • AstraZeneca$332
  • Gilead$232
  • Otsuka America Pharmaceutical, Inc.$152
  • OPKO Pharmaceuticals, LLC$133
  • Bayer$128
  • plus $638 from 13 others

What the payments were for

  • Food & beverage$1,77888%
  • Education$24212%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,020 in reported general payments places this provider in the 60th percentile of 325 nephrology providers in Michigan.

See all nephrology providers in Michigan

Medicare billing

Part B allowed, 2024
$246,593
Medicare patients
453
Services billed
1,706

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol128$94,454
JardianceEmpagliflozin82$81,959
RayaldeeCalcifediol38$55,156
Lanthanum Carbonate11$23,747
EntrestoSacubitril/Valsartan28$18,274
LokelmaSodium Zirconium Cyclosilicate17$15,060
Calcitriol220$5,691
Sevelamer Carbonate13$5,556
Potassium Citrate ErPotassium Citrate32$3,419
Losartan Potassium274$3,256
Potassium Chloride67$2,674
Bumetanide54$1,888
Nifedipine ErNifedipine76$1,751
Valsartan40$1,210
Hydralazine Hcl67$1,045

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$332$109,514145 claims
Boehringer IngelheimJardiance$15$81,95982 claims
OPKO Pharmaceuticals, LLCRayaldee$133$55,15638 claims
ANI Pharmaceuticals, Inc.Valsartan$107$1,21040 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 325 nephrology providers in Michigan.

Other nephrology in Flint

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →